Jacobs Levy Equity Management
ANAB icon

Jacobs Levy Equity Management’s AnaptysBio ANAB Stock Holding History

Jacobs Levy Equity Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.21M Buy
62,336
+33,711
+118% +$2.04M 0.02% 461
2026
Q1 		$1.59M Sell
28,625
-26,463
-48% -$1.42M 0.01% 626
2025
Q4 		$2.67M Sell
55,088
-323,364
-85% -$12.6M 0.01% 536
2025
Q3 		$11.6M Buy
378,452
+10,005
+3% +$230K 0.05% 269
2025
Q2 		$8.18M Buy
368,447
+351,960
+2,135% +$7.37M 0.03% 339
2025
Q1 		$306K Sell
16,487
-68,894
-81% -$1.15M ﹤0.01% 977
2024
Q4 		$1.13M Buy
85,381
+39,307
+85% +$952K ﹤0.01% 695
2024
Q3 		$1.54M Sell
46,074
-1,129
-2% -$38.6K 0.01% 651
2024
Q2 		$1.18M Sell
47,203
-2,186
-4% -$50.9K ﹤0.01% 694
2024
Q1 		$1.11M Buy
49,389
+13,764
+39% +$326K 0.01% 698
2023
Q4 		$763K Sell
35,625
-171,160
-83% -$2.95M ﹤0.01% 769
2023
Q3 		$3.71M Buy
206,785
+8,064
+4% +$154K 0.02% 434
2023
Q2 		$4.04M Buy
198,721
+39,214
+25% +$795K 0.02% 442
2023
Q1 		$3.47M Buy
+159,507
New +$3.88M 0.02% 471
2022
Q3 		– Sell
-15,196
Closed -$308K – 990
2022
Q2 		$308K Sell
15,196
-96,211
-86% -$2.13M ﹤0.01% 921
2022
Q1 		$2.76M Buy
111,407
+22,090
+25% +$669K 0.02% 556
2021
Q4 		$3.1M Buy
89,317
+889
+1% +$28.2K 0.02% 523
2021
Q3 		$2.4M Sell
88,428
-738
-0.8% -$18.7K 0.02% 576
2021
Q2 		$2.31M Sell
89,166
-5,039
-5% -$121K 0.02% 567
2021
Q1 		$2.03M Buy
94,205
+22,827
+32% +$576K 0.02% 595
2020
Q4 		$1.53M Buy
71,378
+527
+0.7% +$12.8K 0.01% 628
2020
Q3 		$1.04M Buy
70,851
+7,260
+11% +$131K 0.01% 655
2020
Q2 		$1.42M Buy
63,591
+29,006
+84% +$530K 0.02% 596
2020
Q1 		$489K Buy
+34,585
New +$525K 0.01% 757

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jacobs Levy Equity Management's ANAB Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its AnaptysBio (ANAB) stake by 118% in Q2 2026, buying an estimated $2.04M and bringing the position to 62,336 shares worth $4.21M. The position accounts for 0.02% of the portfolio, ranked #461.

Jacobs Levy Equity Management first reported a position in ANAB in Q1 2020 and has held it in 24 quarters since. The position peaked at $11.6M in Q3 2025. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Jacobs Levy Equity Management held 62,336 shares of AnaptysBio worth $4.21M as of Q2 2026.
  • Jacobs Levy Equity Management bought 33,711 AnaptysBio shares in Q2 2026, an estimated $2.04M.
  • AnaptysBio made up 0.02% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #461 holding.
  • Jacobs Levy Equity Management first reported a position in AnaptysBio in Q1 2020 and has held it in 24 quarters since.
  • Jacobs Levy Equity Management's AnaptysBio position peaked at $11.6M in Q3 2025.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.